A cross-sectional descriptive study conducted from January 2018 to December 2023 in the internal medicine department and the rheumatology consultation unit of HNZ.

InclusionCriteria:All patients seen in outpatient consultation (medicine or rheumatology) or hospitalized in the internal medicine department of the Zinder National Hospital during the study period and in whom the diagnosis of RA was confirmed according to the clinical and biological approach in accordance with the ACR/EULAR 2010 criteria, satisfying a total score of at least 6 points out of 10 (for early RA) with normal radiographs and in the absence of a diagnosis of another disease) or synovitis associated with typical RA erosion (patients not meeting the conditions for application of the ACR/EULAR criteria).ExclusionCriteria:Those whose assessment (biological and/or imaging) was incomplete.

The parameters of interest were:

Sociodemographic data (age, sex, occupation, education level, background).Clinical data (number of swollen joints, number of painful joints, morning stiffness, joint deformities, and extra-articular signs).Paraclinical data (biology, immunology, imaging).Therapeutic data (treatments received).Evolutional data at 6 months (Disease Activity Index: DAS 28, Health Assessment Questionnaire: HAQ).

Data were entered and analyzed using Epi Info 7. For the descriptive analysis, quantitative variables were expressed as means ± standard deviation or as medians (interquartile ranges) when the distribution was not normal. Qualitative variables were expressed as counts and frequencies. For the analytical part, we first performed univariate analysis using the chi-square test for comparing qualitative variables, the Student’s t-test for comparing means, and the Mann-Whitney U test for non-parametric distributions. When a statistically significant relationship existed between dichotomized variables, we performed multivariate analysis using logistic regression when the dependent variable was qualitative. Candidate variables for the multivariate logistic regression models were selected from among the collected variables based on their clinical relevance and data quality. Variables with more than 20% missing data were excluded. The remaining candidate variables underwent a LASSO-type penalized selection procedure with 10 replicates and cross-validation to identify variables independently associated with the outcome. Results were presented as odds ratios (ORs) with 95% confidence intervals, and model fit was assessed using the Hosmer-Lemeshow test. Linear repression was performed when the dependent variable was quantitative. Odds ratios (ORs) were calculated with 95% confidence intervals (CIs). The test was considered significant if the p-value was less than 0.05.

Patient anonymity and the confidentiality of personal information were protected, and informed consent was obtained. Prior approval was obtained from the HNZ authorities. Research authorization was obtained from the Faculty of Health Sciences.

During the study period (2018-2023), 8935 patients were seen in internal medicine and rheumatology consultations, including 117 cases of RA, representing a hospital frequency of 1.30%.

The mean age of the patients was 45.7 years ± 12.8 years, with a range of 17 to 78 years; the 40 - 60 age group was the largest (58.12%). Females were the most represented (80%), with a sex ratio of 0.25. Housewives were the most numerous group (68.38%). Those with no formal education were predominant (63%). A history of rheumatoid arthritis (18%) and hypertension (17%) were the most frequently reported conditions (Table 1).

Table 1.Distribution of patients according to sociodemographic characteristics, RA study, HNZ, 2018-2023.

HTA: arterial hypertension; PR: rheumatoid arthritis.

Eighty-one percent of patients had a diagnostic delay of between 1 and 25 months. The mean diagnostic delay was 15.7 months, with a range of 2 to 120 months. Thirty-seven (37) patients met the ACR/EULAR criteria, the majority of whom (73%) achieved an ACR/EULAR score of 10 points. Eighty (80) patients were seen at a late stage. Polyarthralgia was the main reason for consultation (74.27%). Inflammatory arthralgia was observed in 54% of patients. Morning stiffness lasted longer than 60 minutes in 73% of cases. Joint deformities were present in 52% of cases. The most frequent deformities of the upper limbs were hammer toes (32.47%), boutonniere deformities (31.62%), and ulnar drift (26.49%). Claw toes were the most frequent deformity (31.62%) in the lower limbs. Extra-articular manifestations (EAMs) were present in 68% of patients. In multivariate analysis, hematological abnormalities represented the most frequent EAMs (59%) (Table 2). Dry eye syndrome was significantly associated with rheumatoid arthritis (RA) activity and diagnostic delay (p < 0.05). Rheumatoid nodules were associated with diagnostic delay (p < 0.05). Anemia was significantly associated with diagnostic delay (p < 0.05) (Tables 3-5).

Table 2.Distribution of patients according to clinical characteristics, RA study, HNZ, 2018-2023.

Table 3. Factors associated with the occurrence of dry eye syndrome, RA study, HNZ, 2018-2023.

DGC: Diagnostic.

Table4. Factors associated with the occurrence of rheumatoid nodules, RA study, HNZ, 2018-2023.

Table 5. Factors associated with the occurrence of anemia, RA study, HNZ, 2018-2023.

Arthritis (RA) was seropositive for rheumatoid factor (RF) in 85% of patients. Anti-CCP antibodies were positive in 90 patients (76.92%). Simultaneous elevation of the erythrocyte sedimentation rate (ESR) and the cytoreductive syndrome (CRP) was found in 90.59% of cases. Anemia was the most frequent blood count abnormality (43%). Microcytic hypochromic anemia was the most common (35.04%). Band-like epiphyseal demineralization was the most frequently observed radiological finding (65%) (Table 6).

Table 6. Distribution of patients according to paraclinical characteristics, RA study, HNZ, 2018-2023.

Analgesics were the most frequently used symptomatic treatment (77%), followed by corticosteroids (67%). Regarding disease-modifying antirheumatic drugs (DMARDs), methotrexate (dose: 10 to 25 mg per week), synthetic antimalarials (SMAs) (dose: 6.5 mg/kg/day divided into two doses), and... Salazopyrine (dose: 40 mg/kg/day divided into two to three doses) was used in 85%, 31% and 18% of patients respectively (Figure 1).

RA was moderately active in 52.99% of patients at the time of diagnosis versus 25.64% after 6 months. A significant decrease in the DAS28-VS score was observed after six months of treatment, from 4.32 ± 1.79 at diagnosis to 2.98 ± 0.71, with a mean change of 1.35 ± 1.67 (paired t-test, p < 0.001) (Table 7). A high risk factor was the most frequently observed poor prognostic factor, observed in 82.05% of cases (Table 8).

Figure 1.Distribution of patients according to therapeutic characteristics, RA study, HNZ, 2018-2023.

Table 7. Distribution of patients according to disease progression characteristics, RA study, HNZ, 2018-2023.

Table 8.Distribution of patients according to poor prognostic factors, RA study, HNZ, 2018-2023.

The prevalence of RA in the general population is between 0.5% and 1% [8][10]. In our series, the hospital prevalence of this condition was 1.3%. This frequency is reported with varying degrees of frequency in hospital series. Thus, Andia et al. in Niamey (Niger) in 2016 [4] found similar results. However, our prevalence is lower than that of Garba et al. [7] in Chad (N’Djamena) in 2026, who find 4.22%, and Salissou et al. [14] in Maradi (Niger) in 2019, who reported 3.7%. This prevalence remains higher than that of the first series of PR documented in Niamey (Niger) by Adehossi et al. [13] in 2010 (8 cases over 1 year) and that of Houzou et al. [15] in Lomé (Togo) (0.45%).

The preferred age range found in this study was 40 - 60 years. Our data are consistent with those in the literature, which state that RA can occur at any age but is most commonly seen between 40 and 60 years of age [3][8].

The mean age of patients at diagnosis was 45.7 years. This data is consistent with that of Andia et al. [4] (45.9 years), but differs from that of the cohorts of Kakpovi et al. [6] (42 years old) and Ouédraogo et al. [11] (48.27 years).

Women represented 80% of the sample with a sex ratio of 0.25, consistent with data from the literature. reported by other African series [4]-[6][14].

Housewives were the most affected in this series (68.38%). This could be explained by the functional impairment caused by the illness, the impact of which on household activities necessitates a consultation.

A history of RA was found in 18% of patients. This is consistent with data from some authors who have described familial forms of RA [13][16]. This finding corroborates the involvement of genetic factors in the pathogenesis of the disease. The other most frequently reported comorbidities in our study were hypertension (17%) and diabetes (7.7%). These comorbidities are reported to varying degrees in the literature. For example, Garba et al. [5] found hypertension and diabetes in 29% and 5% of patients in their series, respectively. Kapovi et al. [6] They also found hypertension (10.9%) and diabetes (4.3%) as comorbidities in the patients in their series. Cardiovascular risk factors are generally the leading causes of morbidity and mortality in rheumatoid arthritis. Hence, the importance of regular and systematic cardiovascular risk assessment [17][18].

The average diagnostic delay (15.7 months) remains high, as already reported in Niger [5][14] and in Togo [6]. This diagnostic delay could be explained by self-medication and the use of traditional medicine, as shown in the work of Garba et al. [5].

In addition to arthralgia, morning stiffness with a loosening time exceeding one hour was present in 73% of patients. These results are comparable to those of a series [19]. A Senegalese study reported a frequency of prolonged morning stiffness in 81% of patients. Rheumatoid arthritis was deforming in 52% of patients. The deformities were predominantly hammer toes (32.47%), boutonniere toes (31.62%), ulnar flexor digitorum profundus (26.49%), and claw toes (31.62%). Similar results were previously observed by Nigerian authors [5][14]. Several lines of evidence agree that diagnosis should be made before these deformities develop, as early diagnosis provides a window of therapeutic opportunity for a better functional and structural prognosis [17][20]. This early diagnosis can be reinforced by Doppler ultrasound or joint MRI, allowing the detection of subclinical synovitis even before the onset of structural lesions [20][21]. These techniques are not available in our setting. Delayed consultation would explain the frequency of these deformities and result in a loss of opportunity for these patients.

Extra-articular manifestations (EAMs) were observed in 68% of cases, the most frequent being hematological (59%), dry eye syndrome (32%), and rheumatoid nodules (19%). The frequency of these EAMs varies from one study to another. Kakpozi et al. [6] reported these MEA. In 48% of patients in their series, the most frequent MEAs were hematological (27.2%), pulmonary (6.5%), and cutaneous (rheumatoid nodules: 2.2%). The most frequent MEAs, as described by Salissou et al. [14], are dry eye syndrome (23.9%), rheumatoid nodules (3.1%), and Felty syndrome (3.1%). Some data in the literature suggest that these MEAs are correlated with RA activity [22][23]. In our series, dry eye syndrome was significantly associated with disease activity (p < 0.001). Some observations in the literature show that these MEAs are more frequent in patients seropositive for rheumatoid factor [24]. In our series, we did not find this association. Some authors support the existence of a relationship between the long duration of RA and the occurrence of MEAs [25][26]. In our series, dry eye syndrome (p < 0.001) and rheumatoid nodules (p = 0.01) were significantly associated with the diagnostic delay.

Standard radiography performed on the majority of our patients showed the classic band-like demineralization (65%), erosions (63%), and joint space narrowing (50%). These lesions are consistent with scientific data [27]. On this subject, Jean et al. [12] reported the same lesions with 45.8% band demineralization, 29.2% erosions, and respectively 33.3% of joint space narrowing. Among these radiological lesions, erosions are of great diagnostic value, particularly those of the head of the 5th metatarsal (Brown’s sign) [20][27]-[29]. Thus, for the European League Against Rheumatism (EULAR), a typical RA erosion is sufficient to support the diagnosis [21][30].

Markers were observed in 90.59% of cases in our series. These results are similar to those reported in the general literature [5][13][14]. This could be explained by the fact that 73% of our patients had moderately to very active rheumatoid arthritis at the time of diagnosis.

In our series, anemia was the most frequently reported blood count abnormality and also the most common MEA, present in 43% of patients. These results are consistent with those of Ankush et al. [31], who report 67% anemia in their series and those of Umaima et al. [32] (65%). This anemia is most often microcytic, as in our study (35%), can be normocytic, but rarely macrocytic. Microcytic anemia is primarily inflammatory. This anemia, common to all chronic inflammatory diseases, is thought by some authors to be associated with rheumatoid arthritis activity [33]. The data from our study are consistent with those of Nikolaisen et al. [34], who found no correlation between anemia and disease activity in their cohort.

Rheumatoid factors (RF) were positive in 85% of patients, and anti-cyclic citrullinated peptide antibodies (Anti-CCP) were positive in 76.92%. These results are comparable to data in the literature. Indeed, Silmani et al. [35] in Algeria reported 78.5% positive rheumatoid factors and 69% positive anti-CCP antibodies; Andia et al. [4] in Niger, 60% of RF were positive, and 4% were anti-CCP; Garba et al. [5] in Niger, 64.70% of RF were positive, and 100% were anti-CCP; Salissou et al. [14] in Niger, 36% of RF tests were positive and 46% were anti-CCP; Ouédraogo et al. [11] in Ouagadougou reported 71.9% RF tests and 87.8% were anti-CCP. This difference in results between studies, particularly regarding anti-CCP, could be explained by the rate at which this testing was performed, which varied from one study to another and depended on the financial resources available to most of our patients at the time of diagnosis.

In the literature, methotrexate is considered the standard first-line treatment. However, other molecules such as leflunomide, sulfasalazine, synthetic antimalarials, and corticosteroids can be used in this line [36]. In our series, all patients were on DMARDS, with 85% on methotrexate, 31% on APS, and 18% on Sulfasalazine. These therapeutic data are reported differently by several studies. In the cohort of Andia et al. [4], 60% of patients are on methotrexate and 40% on APS; Kakpovi et al. [6], 40.2% on methotrexate, 12% on APS, and 5.4% on Sulfasalazine; Garba et al. [5], 64.70% were on methotrexate and 11.76% on antipsychotics. Some learned societies advocate early treatment and even consider it a therapeutic emergency [17][37]. Diagnostic delays in our cohort, as in other African series, could limit the application of these recommendations [5][6][14].

Functionally, the mean initial HAQ score of our patients was 1.73 ± 0.255 [1.09 - 2.17] versus 1.30 ± 0.182 [1.01 - 1.82] at 6 months. Our results differ from those of Salissou et al. [14], who reported a mean initial HAQ score of 2.38 ± 0.54 [0.625 - 2.875] versus 0.64 ± 0.58 [0.125 - 2.50] at 6 months. Regarding disease activity, 73% of patients had moderately to very active RA at the time of diagnosis. The outcome was marked by remission or low disease activity in 56.40% of patients after six months of treatment (P < 0.05). According to the French Society of Rheumatology [17], when the therapeutic goal is not reached after 6 months of treatment, in the presence of poor prognostic factors, the addition of targeted therapy (biological or synthetic) may be indicated. In our series, the goal was not reached after 6 months in 43.60% of patients with at least very high rheumatoid factors (82%) as a poor prognostic factor. In practice, these very expensive targeted therapies are not available in Niger in general, and in Zinder in particular.